ROBERT A. INGRAM

Corporate Board Profile

Tech Score: 0/100

← Back to All Directors

Bausch Health Companies Inc.

Filing Date Source Excerpt
2015-04-09 Mr. Ingram has been serving on the Board of the Company since September 2010, was the Lead Director from September 2010 to December 2010, was the Chairman of the Board from December 2010 to March 2011 and is now our Lead Independent Director. ... Committee Membership and Meeting Attendance: Board - 28/29; Nominating and Corporate Governance Committee - 13/13; Talent and Compensation Committee - 17/18. ... Director Compensation: Fees Earned or Paid in Cash($): 201,547; Stock Awards($): 382,496; Total($): 584,043.
2016-04-29 Mr. Ingram has been serving on the Board since September 2010, was the Lead Director from September 2010 to December 2010, was the Chairman of the Board from December 2010 to March 2011, was the Lead Independent Director from March 2011 to January 2016 and since January 2016 has been our Chairman of the Board.

BIOCRYST PHARMACEUTICALS INC

Filing Date Source Excerpt
2016-04-11 Robert A. Ingram was appointed to the Board in August 2015. ... Mr. Ingram's extensive experience in the pharmaceutical industry as both an executive and director and his private investment expertise contribute valuable insight and expertise to the Board.
2017-04-12 Robert A. Ingram was appointed to the Board in August 2015. ... He serves on the Compensation Committee and Corporate Governance and Nominating Committee. ... 2016 Director Compensation table shows Robert A. Ingram total compensation of $113,740.
2018-09-28 The following table provides information related to the compensation of our non-employee directors during fiscal 2017.
Name Fees Earned ($) Option Award ($) (1) (2) Non-Equity Incentive Plan Compensation All Other Compensation Total ($)
Robert A. Ingram 72,917(3) 104,664 - - 177,581
2019-04-17 Robert A. Ingram was appointed to the Board in August 2015 and was elected Chairman of the Board in May 2017. ... The Company has a Compensation Committee, currently consisting of Dr. Hutson, as its Chairwoman, Mr. Ingram and Mr. Aselage. ... The Company has a Corporate Governance and Nominating Committee consisting of Mr. Abercrombie, as its Chairman, Dr. Hutson, and Mr. Ingram.
2020-03-31 Robert A. Ingram was appointed to the Board in August 2015 and was elected Chairman of the Board in May 2017. ... Mr. Ingram is currently the Chairman of the board of Novan, Inc., a publicly traded late-stage pharmaceutical company focused on dermatology, and Viamet Pharmaceuticals Inc., a private company focused on anti-infective research. ... The Company has a Compensation Committee, currently consisting of Dr. Hutson, as its Chairwoman, Mr. Ingram and Mr. Aselage. ... The Company has a Corporate Governance and Nominating Committee consisting of Mr. Abercrombie, as its Chairman, Dr. Hutson, and Mr. Ingram. ... 2019 DIRECTOR COMPENSATION ... The following table provides information related to the compensation of our non-employee directors during fiscal 2019. ... Robert A. Ingram 95,000 59,088 – – 154,085 ... The Compensation Committee currently consists of Dr. Hutson, as its Chairwoman, Mr. Ingram and Mr. Aselage.
2021-04-13 Robert A. Ingram was initially appointed to the Board in August 2015 and was elected Chairman of the Board in May 2017. ... Mr. Ingram is currently the Chairman of the Board of Black Diamond Therapeutics, Inc. ... The Company has a Compensation Committee, currently consisting of Dr. Hutson, Mr. Aselage, and Mr. Ingram. ... The Company has a Corporate Governance and Nominating Committee consisting of Mr. Abercrombie, as its Chairman, Dr. Hutson, and Mr. Ingram. ... 2020 DIRECTOR COMPENSATION ... Robert A. Ingram 241,560

WOLFSPEED, INC.

Filing Date Source Excerpt
2009-09-04 Mr. Ingram joined the Board of Directors in December 2008. Since January 2003, he has served as Vice Chairman Pharmaceuticals, GlaxoSmithKline.
2010-09-03 Mr. Ingram joined the Board of Directors in December 2008. The members of the Governance and Nominations Committee are Messrs. von Arx, Hosein, Ingram, Plastina, Wagner and Werner. The members of the Compensation Committee are Messrs. Werner, von Arx and Ingram. The following table summarizes the annual and long-term compensation of each of the Company 27s non-employee directors, as well as Dr. Palmour, who served as a director during fiscal 2010. Robert A. Ingram: $303,227.
2011-09-02 Mr. Ingram joined the Board of Directors in December 2008. He serves on the Compensation Committee and Governance and Nominations Committee. Director compensation table shows $451,162 total compensation.
2012-09-05 Mr. Ingram joined the Board of Directors in December 2008. He serves as Lead Independent Director since 2011 and Chairman of the Governance and Nominations Committee.
2013-09-10 Robert A. Ingram. General Partner in Hatteras Venture Partners. Cree Director since 2008.
2014-09-09 Robert A. Ingram. General Partner in Hatteras Venture Partners. Cree Director since 2008. Mr. Ingram joined the Board of Directors in December 2008 and has served as Lead Independent Director since October 2011. The members of the Audit Committee are Messrs. Plastina, Hosein, Ingram and Replogle. The members of the Governance and Nominations Committee are Messrs. Ingram, Hosein, Plastina, Replogle, Tillman, Werner and Ms. Whitaker.
2015-09-08 Robert A. Ingram. General Partner in Hatteras Venture Partners. Cree Director since 2008.
2016-09-06 Robert A. Ingram. General Partner in Hatteras Venture Partners. Cree Director since 2008.
2017-09-08 Robert A. Ingram. General Partner in Hatteras Venture Partners. Cree Director since 2008.

Data sourced from SEC filings. Last updated: 2026-02-03